Episode Description
Some brains carry severe Alzheimer’s pathology while staying cognitively normal, and that paradox forces us to rethink what “prevention” can honestly mean. We map the data behind cognitive reserve, the 2024 Lancet risk factors, the U.S. POINTER lifestyle trial, and the promise and limits of anti-amyloid drugs.
• primary prevention versus secondary prevention definitions
• compression of morbidity as the practical goal
• cognitive reserve as neural “side streets”
• what the Lancet 2024 45% estimate really measures
• why education strengthens cognitive resilience early in life
• hearing loss mechanisms including cognitive load and atrophy
• LDL cholesterol damage to the blood-brain barrier and inflammation
• late-life risks like isolation, smoking, vision loss, air pollution
• U.S. POINTER trial design and what the structured program requires
• why small effect sizes can still matter at scale
• midlife hypertension timing and reverse causation pitfalls
• type 2 diabetes and brain insulin resistance “type 3 diabetes” framing
• anti-amyloid monoclonal antibodies benefits and ARIA risks
• a three-tier framework: strong consensus, emerging science, failed hypotheses
• why passive supplements beat active habits in real-world behavior
go check your blood pressure.
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.
Never miss an episode—subscribe on your favorite podcast app!